Chris Dvergsten

415 total citations
8 papers, 302 citations indexed

About

Chris Dvergsten is a scholar working on Molecular Biology, Surgery and Biological Psychiatry. According to data from OpenAlex, Chris Dvergsten has authored 8 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 2 papers in Surgery and 2 papers in Biological Psychiatry. Recurrent topics in Chris Dvergsten's work include Pain Management and Opioid Use (2 papers), Pain Mechanisms and Treatments (2 papers) and Tryptophan and brain disorders (2 papers). Chris Dvergsten is often cited by papers focused on Pain Management and Opioid Use (2 papers), Pain Mechanisms and Treatments (2 papers) and Tryptophan and brain disorders (2 papers). Chris Dvergsten collaborates with scholars based in United States, Austria and Australia. Chris Dvergsten's co-authors include Joseph Gimbel, M. Hale, Harry Ahdieh, Nashat Gabrail, Bellina Veronesi, W. Wolfgang Fleischhacker, Richard S.E. Keefe, G. C. Dunbar, Jessica S. Beaver and Anthony C. Segreti and has published in prestigious journals such as Diabetes, The Journal of Urology and Schizophrenia Bulletin.

In The Last Decade

Chris Dvergsten

8 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Dvergsten United States	5	128	113	85	73	65	8	302
Javier Muriel Spain	13	121 0.9×	71 0.6×	62 0.7×	98 1.3×	29 0.4×	31	304
Eric S. Hsu United States	9	69 0.5×	54 0.5×	50 0.6×	29 0.4×	24 0.4×	18	257
Fiona A. Bull United Kingdom	5	155 1.2×	41 0.4×	111 1.3×	66 0.9×	67 1.0×	5	399
B. C. Schultheis Australia	2	78 0.6×	92 0.8×	181 2.1×	17 0.2×	18 0.3×	2	273
Ken–ichiro Hayashida Japan	9	50 0.4×	44 0.4×	162 1.9×	25 0.3×	43 0.7×	11	300
R Wörz Germany	10	75 0.6×	112 1.0×	108 1.3×	10 0.1×	28 0.4×	40	278
Yihan He China	7	40 0.3×	52 0.5×	46 0.5×	21 0.3×	33 0.5×	20	355
Christian Cloutier Canada	6	115 0.9×	193 1.7×	168 2.0×	92 1.3×	5 0.1×	7	352
Jordi Cantillo Spain	8	108 0.8×	76 0.7×	33 0.4×	19 0.3×	54 0.8×	16	365
Kai‐Ming Duan China	7	48 0.4×	39 0.3×	21 0.2×	45 0.6×	46 0.7×	9	303

Countries citing papers authored by Chris Dvergsten

Since Specialization

Citations

This map shows the geographic impact of Chris Dvergsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Dvergsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Dvergsten more than expected).

Fields of papers citing papers by Chris Dvergsten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Dvergsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Dvergsten. The network helps show where Chris Dvergsten may publish in the future.

Co-authorship network of co-authors of Chris Dvergsten

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Dvergsten. A scholar is included among the top collaborators of Chris Dvergsten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Dvergsten. Chris Dvergsten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Klein, Klara R., Schafer Boeder, Imogene Dunn, et al.. (2022). Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes. Diabetes Obesity and Metabolism. 24(8). 1439–1447. 7 indexed citations

Buse, John B., Carmen Valcarce, Imogene Dunn, et al.. (2018). Simplici-T1—First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes. Diabetes. 67(Supplement_1). 1 indexed citations

Walling, David P., Stephen R. Marder, John M. Kane, et al.. (2015). Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophrenia Bulletin. 42(2). 335–343. 82 indexed citations

Chancellor, Michael B., Eboo Versi, Chris Dvergsten, & Steven M. Toler. (2015). Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder. The Journal of Urology. 194(5). 1329–1335. 1 indexed citations

Hosford, David A., Chris Dvergsten, Jessica S. Beaver, et al.. (2014). P.3.d.018 Phase 2 clinical trial of TC-5619, an alpha 7 nicotinic receptor agonist in the treatment of negative and cognitive symptoms in schizophrenia. European Neuropsychopharmacology. 24. S531–S532. 3 indexed citations

Hale, M., Chris Dvergsten, & Joseph Gimbel. (2004). Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. Journal of Pain. 6(1). 21–28. 131 indexed citations

Gabrail, Nashat, Chris Dvergsten, & Harry Ahdieh. (2004). Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Current Medical Research and Opinion. 20(6). 911–918. 60 indexed citations

Veronesi, Bellina & Chris Dvergsten. (1987). TRIPHENYL PHOSPHITE NEUROPATHY DIFFERS FROM ORGANOPHOSPHORUS‐INDUCED DELAYED NEUROPATHY IN RATS. Neuropathology and Applied Neurobiology. 13(3). 193–208. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact